BioCentury
ARTICLE | Clinical News

Toremifene citrate regulatory update

March 9, 2009 7:00 AM UTC

GTx said FDA gave an NDA for toremifene 80 mg to prevent bone fractures in men with prostate cancer on androgen deprivation therapy a standard review, resulting in a PDUFA date of Oct. 30. GTx had req...